Faricimab is a bispecific antibody that simultaneously targets Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), exhibiting a favorable safety and tolerability profile. This therapeutic agent is designed to inhibit retinal vascular leakage, cell death, and inflammation, which are critical pathological factors in retinal ischemia/reperfusion (I/R) injury and subretinal choroidal neovascularization (sCNV) in mouse models. Clinical studies have shown that Faricimab offers statistically significant improvements in visual acuity compared to Ranibizumab. It is indicated for the treatment of various retinal diseases, including wet age-related macular degeneration (w-AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), making it a valuable tool in ophthalmic research and therapeutic applications.
Faricimab is a bispecific antibody that simultaneously targets Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), exhibiting a favorable safety and tolerability profile. This therapeutic agent is designed to inhibit retinal vascular leakage, cell death, and inflammation, which are critical pathological factors in retinal ischemia/reperfusion (I/R) injury and subretinal choroidal neovascularization (sCNV) in mouse models. Clinical studies have shown that Faricimab offers statistically significant improvements in visual acuity compared to Ranibizumab. It is indicated for the treatment of various retinal diseases, including wet age-related macular degeneration (w-AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), making it a valuable tool in ophthalmic research and therapeutic applications.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
